Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 405 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Immune Deficiency Disease Clear all
Not listed No phase listed Observational

A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders

NCT00596999
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
UCB and HPDSC
Procedure
Lead sponsor
Celgene Corporation
Industry
Eligibility
Up to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Oct 1, 2026, 9:53 AM EDT
Terminated Phase 2 Interventional Results available

Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim

NCT01182675
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 3 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 1, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

NCT01313507
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
NewGam
Biological
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Irvine, California • Centennial, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 1, 2026, 9:53 AM EDT
Completed No phase listed Observational

An Observational Study of People Who Have Recently Been Infected With HIV

NCT00103961
View directory record Official record
Conditions
HIV Infections
Interventions
Questionnaire
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Oct 1, 2026, 9:53 AM EDT
Active, not recruiting Phase 3 Interventional

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

NCT06076642
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
TAK-881, Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Irvine, California • Walnut Creek, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 1, 2026, 9:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

NCT00546871
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Intravenous (Human), 10%
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
24 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 1, 2026, 9:53 AM EDT
Completed Phase 1Phase 2 Interventional

Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome

NCT01410825
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome
Interventions
Retrovirus-mediated gene transfer
Biological
Lead sponsor
David Williams
Other
Eligibility
3 Months to 35 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 1, 2026, 9:53 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

NCT01852370
View directory record Official record
Conditions
Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified, Severe Chronic Neutropenia, Chronic Granulomatous Disease (CGD), Hyper IgE Syndromes, Hyper IgM Deficiencies, Wiskott-Aldrich Syndrome, Mendelian Susceptibility to Mycobacterial Disease, Common Variable Immune Deficiency (CVID)
Interventions
CD3/CD19 negative allogeneic hematopoietic stem cells
Biological
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 1, 2026, 9:53 AM EDT
Recruiting No phase listed Observational

Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform

NCT06999954
View directory record Official record
Conditions
Shwachman-Diamond Syndrome, SDS, IBMF, Congenital Neutropenia, Heme Malignancy, Shwachman Syndrome, Inherited Bone Marrow Failure, Exocrine Pancreatic Insufficiency, WHIM, ELANE, SBDS Gene Mutation, EFL1 Gene Mutation, DNAJC21 Gene Mutation, SRP54 Gene Mutation, Inherited Cancer Syndrome, Inherited Cancer-Predisposing Syndrome, Neutropenia, Severe Chronic, Neutropenia Other, Neutropenia Chronic Benign, Ribosome Alteration, Ribosomopathy, Immune Deficiency, Inherited BMF Syndrome, Inherited Immunodeficiency Diseases, Cognitive Delay, Mild, Myelodysplastic Syndromes, Pancytopenia
Interventions
Not listed
Lead sponsor
Shwachman-Diamond Syndrome Alliance Inc
Other
Eligibility
Not listed
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2088
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 1, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00262080
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide, Phosphate Buffer Saline (PBS),
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 1, 2026, 9:53 AM EDT
Completed Phase 3 Interventional

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

NCT04502030
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Hypogammaglobulinemia
Interventions
Panzyga, Placebo
Biological · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
15
States / cities
St. Petersburg, Florida • Columbus, Georgia • Macon, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 1, 2026, 9:53 AM EDT
Completed Phase 4 Interventional

Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis

NCT00000816
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Sulfamethoxazole-Trimethoprim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
40
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 1, 2026, 9:53 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

NCT04554914
View directory record Official record
Conditions
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
Interventions
Tabelecleucel
Biological
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
Not listed
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 1, 2026, 9:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Magnesium Supplementation in People With XMEN Syndrome

NCT02496676
View directory record Official record
Conditions
XMEN
Interventions
Magnesium L-threonate, Placebo, Intravenous (IV) magnesium sulfate (MgSO4)
Dietary Supplement · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 1, 2026, 9:53 AM EDT
Active, not recruiting Phase 3 Interventional

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

NCT06634420
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
NTLA-2002, Normal Saline IV Administration
Biological
Lead sponsor
Intellia Therapeutics
Industry
Eligibility
16 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 1, 2026, 9:53 AM EDT
Completed No phase listed Observational

Learning and Behavior Problems in Children With Chronic Granulomatous Disease and Related Disorders

NCT00005933
View directory record Official record
Conditions
Chediak Higashi Syndrome, Chronic Granulomatous Disease, Job's Syndrome, Leukocyte Disorder
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 1, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

NCT02810444
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
IgG Next Generation (BT595)
Biological
Lead sponsor
Biotest
Industry
Eligibility
2 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Centennial, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 1, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV

NCT00084149
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, and Zidovudine, Lopinavir/Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Minneapolis, Minnesota • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 1, 2026, 9:53 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States

NCT00266513
View directory record Official record
Conditions
Hyper-IgM Syndrome, Ectodermal Dysplasia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 1, 2026, 9:53 AM EDT
Completed Phase 2 Interventional

A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS

NCT00000975
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Itraconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 1, 2026, 9:53 AM EDT
Recruiting Phase 3 Interventional

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

NCT07266805
View directory record Official record
Conditions
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
San Diego, California • Walnut Creek, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 1, 2026, 9:53 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

NCT01457430
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Icatibant
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Wheaton, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 1, 2026, 9:53 AM EDT
Completed No phase listed Observational

The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration

NCT00227357
View directory record Official record
Conditions
HIV Infections, AIDS, Opiate Dependence, Post-Traumatic Stress Disorders
Interventions
On-site - buprenorphine/naloxone (Suboxone), Off-site - methadone or no agonist
Drug
Lead sponsor
Ruth M. Rothstein CORE Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Oct 1, 2026, 9:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

SCID Bu/Flu/ATG Study With T Cell Depletion

NCT02127892
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
unrelated BM with T cell depletion, unrelated cord blood, haplo BM with T cell depletion, unrelated PBSC with T cell depletion
Biological · Device
Lead sponsor
Neena Kapoor, M.D.
Other
Eligibility
Up to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 1, 2026, 9:53 AM EDT